LC-MS/MS assay for N1-methylnicotinamide in humans, an endogenous probe for renal transporters.
Bioanalysis
; 10(9): 673-689, 2018 May 01.
Article
en En
| MEDLINE
| ID: mdl-29749253
ABSTRACT
BACKGROUND:
N1-methylnicotinamide (1-NMN) has been proposed as a potential clinical biomarker to assess drug-drug interactions involving organic cation transporters (OCT2) and multidrug and toxin extrusion protein transporters.RESULTS:
A hydrophilic interaction liquid chromatography-MS/MS assay, to quantify 1-NMN, in human plasma and urine is reported. MATERIALS &METHODS:
A hydrophilic interaction chromatography (HILIC)-tandem mass spectrometry (MS/MS) assay to quantify 1-NMN in human plasma and urine is reported. The basal 1-NMN levels in plasma and urine were 4-120 and 2000-15,000 ng/ml, respectively.CONCLUSION:
1-NMN plasma AUCs increased two- to fourfold versus placebo following the administration of a clinical candidate that in vitro experiments indicated was an OCT2 inhibitor. The described hydrophilic interaction liquid chromatography-MS/MS assay can be used to assess a clinical compound candidate for the inhibition of OCT2 and multidrug and toxin extrusion protein transporter in first-in-human studies.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Niacinamida
/
Biomarcadores Farmacológicos
/
Transportador 2 de Cátion Orgánico
/
Riñón
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Bioanalysis
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos